

# Jesse G Dixon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5559931/publications.pdf>

Version: 2024-02-01

18  
papers

606  
citations

933447

10  
h-index

888059

17  
g-index

19  
all docs

19  
docs citations

19  
times ranked

1077  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 60-67.	6.3	5
2	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. <i>Blood</i> , 2022, 139, 1684-1693.	1.4	56
3	End of induction positron emission tomography complete response (PET- $\text{CR}$ ) as a surrogate for progression-free survival in previously untreated follicular lymphoma. <i>British Journal of Haematology</i> , 2022, 198, 333-337.	2.5	2
4	CODEL: phase III study of RT, RT+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. <i>Neuro-Oncology</i> , 2021, 23, 457-467.	1.2	58
5	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 400-407.	6.3	44
6	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704.	6.3	25
7	Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. <i>Cancer Medicine</i> , 2020, 9, 7935-7942.	2.8	19
8	International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. <i>Blood</i> , 2020, 135, 2041-2048.	1.4	158
9	A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. <i>Cancer</i> , 2019, 125, 3790-3800.	4.1	51
10	Phase III trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). <i>Journal of Neuro-Oncology</i> , 2019, 143, 573-581.	2.9	7
11	Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3502-3502.	1.6	5
12	A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group. <i>Blood</i> , 2019, 134, 2812-2812.	1.4	0
13	Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). <i>Journal of Clinical Oncology</i> , 2018, 36, 2593-2602.	1.6	59
14	Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3603-3603.	1.6	4
15	Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3601-3601.	1.6	0
16	Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1173-1178.	0.8	69
17	Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 124-128.	2.3	37
18	Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy $\pm$ biologic: Findings from 9,092 pts in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3535-3535.	1.6	6